| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2125493 | European Journal of Cancer | 2007 | 10 Pages |
Abstract
The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases I and II clinical trials. Interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hermien Hartog, Jelle Wesseling, H. Marike Boezen, Winette T.A. van der Graaf,